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The in vivo imaging probe [11C]-PIB (Pittsburgh Compound B, N-methyl[11C]2-(40 -methylaminophenyl-6 -
hydroxybenzathiazole) is under evaluation as a key imaging tool in Alzheimer’s disease (AD) and to date has
been assumed to bind with high affinity and specificity to the amyloid structures associated with classical pla-
ques (CPs), one of the pathological hallmarks of the disease. However, no studies have systematically investi-
gated PIB binding to human neuropathological brain specimens at the tracer concentrations achieved during
in vivo imaging scans.Using a combination of autoradiography and histochemical techniques, we demonstrate
that PIB, in addition to binding CPs clearly delineates diffuse plaques and cerebrovascular amyloid angiopathy
(CAA).The interaction of PIB with CAAwas not fully displaceable and this may be linked to the apolipoprotein
E-e4 allele. PIB was also found to label neurofibrillary tangles, although the overall intensity of this binding was
markedly lower than that associated with the amyloid-beta (Ab) pathology.The data provide a molecular expla-
nation for PIB’s limited specificity in diagnosing and monitoring disease progression in AD and instead indicate
that the ligand is primarily a non-specific marker of Ab-peptide related cerebral amyloidosis.
Keywords: PIB; amyloid; Alzheimer’s disease; positron emission tornography; imaging
Abbreviations: AD=Alzheimer’s disease; ApoE=apolipoprotein E; Ab=amyloid-beta peptide; BTA-1=2-(40 -methylami-
nophenyl)benzothiazole; CAA=cerebrovascular amyloid angiopathy; CAA-NDB=CAA-associated non-displaceable binding;
CPs=classical plaques; DLB=dementia with Lewy bodies; DPs=diffuse plaques; ECX=entorhinal cortex; FDDNP=2-(1-{6-
[(2-fluoroethyl(methyl)amino]-2-naphthyl}ethylidene)malononitrile; FTD= frontotemporal dementia; MFG=mid-frontal
gyrus; NFTs=neurofibrillary tangles; NDB=non-displaceable binding; OCL = occipital lobe; PET=positron emission
tomography; PIB=Pittsburgh Compound-B (2-[40 -(methylamino)phenyl]-6 -hydroxybenzothiazole); rCMRglc=regional
cerebral glucose metabolism rate; SB13=4-N-methylamino-40 -hydroxystilbene; SPL= superior parietal lobe; SPs= senile
plaques
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Introduction
Amyloid-beta (Ab) peptide deposition in senile plaques
(SPs, for plaque terminology see ‘Methods’ section), and
the formation of neurofibrillary tangles (NFTs) from tau
are the key histopathological features for the diagnosis of
Alzheimer’s disease (AD) (Mott and Hulette, 2005). Great
efforts are currently underway to define reliable biomarkers
to establish the diagnosis of AD intra vitam and in early
disease phases, a prerequisite for the development of
disease-modifying therapies.
Amyloid is a generic term used to describe polypeptide
filaments that are folded into a cross b-sheet structure and as
a consequence bind dyes such as Congo Red and the
Thioflavins S and T (Lockhart, 2006). Both Ab, which forms
the fibrils variably associated with SPs (and cerebrovascular
amyloid), and tau, which forms the paired helical and
straight filaments associated with NFTs, are types of amyloid
(Serpell, 2000; Berriman et al., 2003; Barghorn et al., 2004).
[11C]-PIB is one of a number of positron emission
tomography (PET) imaging probes that were derived from
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Thioflavin T and the radiotracer is thought to selectively
bind to the highly fibrillar (i.e. amyloid rich) SP subtype
known as classical plaques (CPs) (Mathis et al., 2004).
In support of this premise a series of reports have
demonstrated the increased, region specific, retention of
[11C]-PIB in clinically diagnosed AD patients compared
with non-demented control groups (Klunk et al., 2004;
Verhoeff et al., 2004; Archer et al., 2006; Engler et al., 2006;
Fagan et al., 2006; Edison et al., 2007) in a pattern that
broadly matches CP distribution (Nordberg, 2004).
Additionally, an inverse correlation of PIB retention with
the pattern of decreased regional cerebral glucose metabo-
lism rate (rCMRglc) has been observed (Klunk et al., 2004;
Buckner et al., 2005; Engler et al., 2006; Edison et al., 2007).
Finally, a 2-year-follow-up study on a cohort of AD
patients indicated that the amyloid load, as measured by
[11C]-PIB, remained stable irrespective of clinical progres-
sion determined by both cognitive measures and rCMRglc
(Engler et al., 2006). These latter two findings in particular
suggest that amyloid deposition, as detected by PIB, is an
early event in the pathogenesis of AD that may (i) precede
a decline in cognitive function and (ii) reach an early
plateau which then remains stable.
However, reconciling these global, in vivo observations
with data from both the large number of antecedent post-
mortem studies detailing the regional, microscopic spread of
AD pathology (Braak and Braak, 1991a; Berg et al., 1998;
Price and Morris, 1999) and the relatively sparse literature
characterizing the interaction of imaging probes with
amyloid lesions (Lockhart, 2006) highlights a number of
important discrepancies. First, the high retention of
[11C]-PIB in brain regions not normally associated with a
high CP load such as the striatum and frontal cortex (Klunk
et al., 2004; Nordberg, 2004; Buckner et al., 2005; Engler
et al., 2006; Edison et al., 2007) cannot readily be explained
by the reported specificity of PIB for CPs. For example
studies have demonstrated that the vast majority of plaques
in the striatum are of a diffuse plaque (DP) type (Wisniewski
et al., 1989; Suenaga et al., 1990) and that CPs are not a
dominant pathological feature of the frontal cortex during
the early stages of AD (Mochizuki et al., 1996; Berg et al.,
1998; Price and Morris, 1999). However, the findings
associated with this latter observation are not universal
(Braak and Braak, 1991a; Markesbery et al., 2006). Secondly,
the dichotomy of the ligand retention pattern into essentially
‘PIB-positive’ or ‘PIB-negative’ is at odds both with the
central role of the CP in disease progression (Selkoe and
Schenk, 2003). A number of studies have also demonstrated
that CPs begin to form near the time of clinical presentation
and then increase with disease severity (Braak and Braak,
1991a; Berg et al., 1998; Price and Morris, 1999). Thirdly, a
‘pathologic’ or ‘PIB-positive’ retention pattern has also been
identified in 22 to 40% of cognitively normal individuals
(Fagan et al., 2006; Mintun et al., 2006; Rowe et al., 2007)
and this represents a significant false positive rate. As no
longitudinal PIB-PET data is available from these cognitively
normal subjects, it is currently unclear whether these findings
reflect the molecular development of prodomal AD (Barnes
et al., 2006) or are consistent normal ageing. Finally, only
one imaging study to date has considered the potential
influence of the apolipoprotein E (ApoE)-e4 allele on the
pattern of PIB retention (Rowe et al., 2007), as this variant is
linked with an earlier disease onset, a more rapid cognitive
decline, and a more pronounced accumulation of both SPs
and cerebrovascular amyloid angiopathy (CAA) (Berg et al.,
1998; Attems, 2005). These issues are further exemplified by
the application of [11C]-PIB in non-AD patient populations
such as dementia with Lewy bodies (DLB) and frontotem-
poral dementia (FTD) (Bacskai et al., 2007; Rowe et al.,
2007; Rabinovici et al., 2007).
In order to address these important knowledge gaps an
autoradiography study was undertaken using a tritium
labelled preparation of the PIB ([3H]-PIB) and fresh-frozen
brain sections from cases containing AD-associated neuro-
pathological lesions (SPs, CAA and NFTs). Importantly the
study utilized subjects of known ApoE genotype, a tracer
concentration of radioligand relevant to imaging studies
(Mathis et al., 2004; Rowe et al., 2007) and histological
examination of adjacent sections, so that radiolabelled
features could be positively linked to specific lesions.
Methods
Compounds
Tritiated Pittsburgh Compound-B ([3H]-PIB, N-methyl-[3H]2-
(40-methylaminophenyl)-6-hydroxybenzothiazole was prepared as a
custom synthesis by GE Healthcare UK Ltd (Little Chalfont, UK) at
a specific activity 71Ci/mmol (2.63TBq/mmol). BTA-1, 2-(40-
methylaminophenyl)benzothiazole (Sigma, Poole, UK) was prepared
as a 10mM stock in dimethylsulphoxide and stored at 20C.
Preparation of cryosections
Fresh, frozen brain tissues were obtained from the Brain Donation
Program at Sun Health Research Institute (Sun City, AZ, USA).
Four consecutive cryosections (8–10 mm thickness) were prepared
from each brain specimen and mounted onto statically charged
(‘plus’) glass slides prior to airtight storage with desiccants at
80C. The first and third sections in each series were used for
histochemical analysis. The second and the fourth sections were
used for radioligand binding studies defining the total ([3H]-PIB)
and non-displaceable binding (NDB) ([3H]-PIB plus BTA-1)
signals, respectively.
Radiolabelling of sections
Slides were thawed for 10min at room temperature (25C) prior
to incubation in PBS/E buffer [phosphate buffer saline (PBS)
containing 10% v/v ethanol, pH 7.2] for 15min at room
temperature. Slides were then incubated with 0.5 nM [3H]-PIB
(total binding) or 0.5 nM [3H]-PIB plus 10 mM BTA-1 (NDB) for
60min at room temperature and then terminated by consecutive
30 s incubations in PBS/E (2) and distilled water (all at 4C).
Slides were dried under a cold air stream and then apposed with
Hyperfilm-3H (GE/Amersham, RPN535B: early availability batch).
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Film development and analysis
Films were developed after an 8-week exposure using GBX
developer solutions (Kodak, New Haven, USA). Images of the
autoradiographs were captured using the MCID digital densito-
metry system (Interfocus, Linton, UK). No manipulations other
than optimization of lighting conditions (for image capture),
image cropping and re-sizing were performed.
Nomenclature and classification
of pathological features
The identification of SPs, CAA and NFTs was based on data from
two separate staining techniques (Table 1) as well as morpholo-
gical appearance. The terminology for SP phenotypes follows that
of Berg et al. (1998). Plaques with generally spherical shapes
displaying strong staining with both Thioflavin S and the anti-Ab
monoclonal antibody 6E10 were defined as classical plaques (CPs).
CPs were not further differentiated into neuritic and cored
plaques. Plaques with spherical or irregular shapes displaying weak
staining for Thioflavin S and weak-to-moderate staining with 6E10
were defined as diffuse plaques (DPs). Senile plaques (SPs) are
used as a generic term to encompass both types of plaque lesions
(i.e. CPs and DPs). CAA was identified on the basis of strong
staining with 6E10 and Thioflavin S, and was differentiated from
CPs on the basis of morphological appearance. NFTs were
identified by Gallyas and Thioflavin S staining.
Histochemical procedures
All procedures were performed at room temperature unless
otherwise noted.
Thioflavin S staining
Thioflavin S is a stain used to detect lesions containing high
amounts of amyloid structures and will primarily label CPs, CAA
and NFTs (Dickson, 2005). DPs contain low amounts of amyloid
structure and only stain weakly with this dye (Dickson, 2005).
Sections were removed from the freezer and immediately
immersed for 30min in 4% formaldehyde, freshly prepared from
paraformaldehyde crystals and buffered to pH 7.4. Following
washes in PBS and partial drying at room temperature, the
sections were defatted in 1:1 chloroform/ethanol for 1 h, washed
briefly twice in 100% ethanol and then hydrated through graded
alcohols to water. Sections were then stained in 0.1% Thioflavine
S for 10min, differentiated rapidly in 80% ethanol and cover-
slipped with Apathy’s medium.
Immunohistochemical staining for A peptide
using 6E10
The anti-Ab monoclonal antibody 6E10 is considered a sensitive
marker for CPs and CAA, but may stain diffuse deposits less
intensely (Dickson, 2005). Washes were performed between all
steps with PBS containing 0.1% Triton X-100. Sections were
removed from the freezer and immediately immersed in 70%
ethanol for 2min. Endogenous peroxidase was then suppressed by
immersion in 1% hydrogen peroxide for 30min. After additional
washes, sections were incubated overnight in 6E10 (CHEMICON
International, Temecula, USA) diluted 1:1000 and detected using
VECTASTAIN Elite ABC Kit (Vector Laboratories, Burlingame,
USA), dehydrated and mounted in Permount (Fisher Scientific,
Fair Lawn, USA).
Gallyas staining
The Gallyas method is a silver-staining technique that in this form
is considered specific for NFTs (Braak and Braak, 1991b; Dickson,
2005). Sections were removed from the freezer and fixed as
described earlier for Thioflavin S staining. The staining protocol
was as described (Braak and Braak, 1991b) with the addition of
two pre-treatment steps to minimize non-specific red blood cell
staining. These consisted of immersion in 0.25% potassium
permanganate for 4min followed by incubation in 5% oxalic
acid for 5min.
Results
The neuropathological lesions under investigation were
studied using four different brain regions: Category A,
SP-predominant pathology used mid-frontal gyrus (MFG);
Category B, Mixed pathology (DPs, CPs, CAA and NFTs)
used superior parietal lobe (SPL); Category C, CAA-
predominant pathology used occipital lobe (OCL); and
Category D, NFT-predominant pathology used entorhinal
cortex (ECX). The neuropathological sections under
investigation were pre-selected for the presence of the
desired neuropathological lesions and were as far as possible
derived from cases with pathologically confirmed AD.
However, given the considerable intermingling of lesion
types in AD cases and a desire to sample each lesion type in
a relatively pure form it was necessary to use additional
neuropathological disease groups. A total of 16 cases (four
per category) were analysed in the study and representative
data from two cases from each category A–D are reported
here in detail (Table 2). A full listing of all 16 cases is
provided in the supplementary data.
Category A sections
(SP-predominant pathology)
The interaction of [3H]-PIB (0.5 nM) with relatively pure
populations of SPs (i.e. a mixture of DPs and CPs) was
investigated using sections from the MFG of cases with
Table 1 Summary of histological and immunohistological
staining techniques used to identify neuropathological
lesions
Ab immunostain (6E10) Thioflavin S Gallyas
CPs ++ ++ N/A
DPs +, +/ +/ N/A
CAA ++ ++ N/A
NFTs N/A ++ ++
Note: As noted in the ‘Methods’ section both the morphology and
differential staining intensity (++ strong staining, + moderate
staining, +/ weak staining, N/A not applicable) were used to
distinguish between lesion types.
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probable AD (Table 2). Both cases demonstrated an intense
punctate labelling with [3H]-PIB (Fig. 1A and D) that was
strongly associated with the cortical region, although there
was also a sparse labelling extending into the immediate
subcortical white matter (Fig. 1D, case A2). As demon-
strated by the labelling reactions performed in the presence
of cold competitor ligand (BTA-1, 10 mM) the vast majority
of the binding signal in both the grey and white matter was
fully displaceable (Fig. 1B and E).
Alignment of the autoradiography images with the 6E10
(Ab) immunohistochemistry of the adjacent sections (Fig. 1C
and F) indicated a substantial overlap with the punctate
staining pattern observed with [3H]-PIB and that this
extended across both the white and grey matter lesions.
This low-magnification correlation was also confirmed by
the higher magnification images (Fig. 1G, case A2). However,
it is also clear from these images that there are some areas
which although intensely labelled with [3H]-PIB display
reduced 6E10 immunoreactivity and this may in part reflect
the enhanced sensitivity of the autoradiography method.
Consistent with its known poor sensitivity for DPs
(Dickson, 2005) Thioflavin S only strongly labelled the
sparse CPs (and CAA) associated with this case (Fig. 1G).
Nevertheless there was good correspondence between the
radiotracer and all forms of Ab pathology examined. The
ability of [3H]-PIB to label DPs more intensely than
Thioflavin S probably reflects the >100-fold higher affinity
of radioligand for Ab fibrils relative to the dye (Lockhart
et al., 2004). This dataset demonstrates that at typical
tracer concentrations [3H]-PIB can bind not only CPs but
also DPs.
Category B sections [mixed pathology
(DPs,CPs,CAA,NFTs)]
Sections from the SPL were pre-selected for the presence of
all lesion types under investigation. The low-magnification
images of sections labelling with [3H]-PIB were again very
similar to those obtained with the MFG. A dense, punctate
cortical staining pattern was observed (Fig. 2A and D) that
was, in most instances, fully displaceable and which largely
overlapped with the 6E10 labelled sections (Fig. 2C and F).
Two features however differentiated these sections from the
Category A cases (Fig. 1).
Table 2 Neuropathological characteristics of sections
Case Brain region Pathology scores of sections used in study ApoE status CAA-NDB Neuropathological diagnosis
DP CP NFT CAA
A1 MFG +++ ++   4/4 N.A. Probable AD
A2 MFG +++ +  + 3/4 Yes Probable AD
B1 SPL +++ +++ + +++ 4/4 Yes Definite AD
B2 SPL +++ +++ + ++ 4/4 Yes Definite AD
C1 OCL ++ ++  ++ 2/3 No Possible AD
C2 OCL    +++ 4/4 Yes Probable AD
D1 ECX   +++  2/3 N.A. Not AD
D2 ECX   +  / N.A. Not AD
Note: Pathology scores: +++, frequent. ++, moderate. +, sparse. , absent. Note that the neuropathological diagnosis for each case
was based on a full pathological examination according to Consortium to Establish a Registry for AD criteria (Mirra et al., 1991).
Note that no ApoE genotyping data was available for case D2. N.A., not applicable as CAA absent on these sections. An expanded












Fig. 1 Images of adjacent MFG sections from two Category A
pathology cases (A1 inA^C; A2 inD^G), showing correspondence
of [3H]-PIB binding (A and D) with 6E10-immunoreactive Ab
deposits (C and F). NDB is demonstrated in sections treated with
the non-radioactive competitive ligand BTA-1 (B and E). Black
arrows demonstrate a number of specific corresponding features.
Asterisks mark staining artefacts on 6E10 sections. Higher power
representative images of boxed area from case A2 arranged in
consecutive cryostat order (G). Selected corresponding pathologi-
cal features are highlighted in pink (DPs), orange (CPs) and blue
(CAA). Scale bar 1mm.
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First, a number of radiolabelled foci were more obviously
retained on the sections incubated with cold competitor
ligand (Fig. 2B and E), which as discussed in the Category
C cases coincided with CAA. Secondly, the intense labelling
observed with [3H]-PIB along the cortical surface of case
B2 (Fig. 2D) was associated with a band of weakly 6E10
immunoreactive material (Fig. 2F). Higher power images of
the 6E10 sections indicated the presence of subpial ‘band’
or ‘ribbon-like’ Ab diffuse deposits associated with the
outer portion of the cortical molecular layer (layer 1)
(Fig. 2G). The Ab deposits in subpial lesions have been
demonstrated to be diffuse, with only small amounts of
amyloid fibrils present (Yamaguchi et al., 1991). This
finding reinforces our previous contention that PIB will
also be sensitive in vivo to ‘diffuse’ deposits.
Although Gallyas staining revealed the presence of NFTs
in both cases (Table 2) it was not possible to clearly assign
any of the [3H]-PIB labelling with this pathological feature
due to the high density, close proximity and greater size of
the Ab lesions. However, as demonstrated for the Category
D cases [3H]-PIB clearly labels NFTs [see ‘Category D
sections (NFT-predominant pathology) section].
Category C sections
(CAA-predominant pathology)
The OCL is frequently and severely affected by cerebrovas-
cular amyloid deposition in normal ageing and a range of
neurodegenerative diseases such as AD (Attems, 2005).
Sections labelled with [3H]-PIB from each of the cases
displayed strong, punctate staining that at low magnifica-
tion was broadly similar to the cortical patterns associated
with the Category A and B cases (Fig. 3A and D). There
was, however, a marked difference in the CAA labelling
pattern in the presence of cold competitor ligand. While
there was almost complete displacement of the radiolabel in
case C1 (Fig. 3B), case C2 retained significant areas of
radiolabel, although the overall intensity of the labelled
structures was visibly reduced (Fig. 3E). Additional staining
of adjacent sections with both 6E10 and Thioflavin S
confirmed the presence of Ab positive, amyloidotic blood
vessels and that the foci of radiolabel retained after
treatment with the cold competitor compound remained
associated with these structures (Fig. 3G). These features
are termed the CAA-associated non-displaceable binding
(CAA-NDB).
Although the origins of the CAA-NDB cannot be fully
addressed in this study, given the relatively small number of
cases examined, one obvious difference between these two
cases was their ApoE status. Cases C1 (CAA-NDB negative)
and C2 (CAA-NDB positive) were e2/e3 and e4/4,
respectively. Both the remaining two category C cases
were negative for CAA-NDB and possessed e3/e3 genotypes
(see supplementary data Table). Across the remaining
categories CAA pathology was present only in case A2
and cases B1-4. All of these CAA cases were positive for
CAA-NDB and contained at least one e4 allele. Although
provocative, further detailed analysis is clearly required to
understand the origins of the CAA-NDB.
Category D sections
(NFT-predominant pathology)
Hyperphosphorylated tau proteins, the major components
of NFTs, are folded into an amyloid structure and thus









Fig. 2 Images of adjacent SPL sections from two Category B
pathology cases (B1 inA^C; B2 inD^G), showing correspondence
of PIB binding (A and D) with 6E10-immunoreactive Ab deposits
(C and F). NDB is demonstrated in sections treated with the
non-radioactive competitive ligand BTA-1 (B and E). Arrows
demonstrate a number of specific corresponding features,
including subpial diffuse amyloid deposits (black arrows on left of
D and F). Note that on both sections a considerable number of
PIB-labelled areas are not completely displaced by the cold BTA-1
compound and that these additionally coincide with 6E10-labelled
foci (black arrows on B). Higher power representative images of
boxed area from case B2 arranged in consecutive cryostat order
(G). Selected corresponding pathological features are highlighted
in pink (DPs), orange (CPs) and blue (CAA).The pink bar and
arrows demonstrate corresponding staining of a subpial band
of diffuse plaques. Scale bar 1mm.
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appears to be particularly susceptible to the formation of
NFTs (Braak and Braak, 1992) and the cases associated with
this category were pre-selected for their absence of Ab
pathology. Associated with case D1 a diffuse, interrupted
band of PIB labelling was observed running along the
superficial cortical layers (Fig. 4A). Incubation with cold
competitor ligand demonstrated that the binding of
[3H]-PIB to this lesion was fully displaceable (Fig. 4B).
Consistent with its sparse pathological scoring for NFTs
(Table 2), case D2 displayed a more discrete punctate
labelling with [3H]-PIB that was again associated with
the superficial cortical layers and fully displaceable (Fig. 4C
and D).
Higher magnification images of the adjacent sections
from case D1, labelled with Thioflavin S and Gallyas stains,
confirmed the presence of an amyloid structure and NFTs,
respectively, that were intimately associated with [3H]-PIB
(Fig. 4E). The observed labelling pattern is consistent with
localization of the radioligand to the ‘stellate cell islands’
found in the pre-alpha layer (layer II) of the ECX and that
as this layer sweeps laterally the ‘islands’ disappears and are
replaced by a non-interrupted neuronal band that plunges
diagonally through the transentorhinal cortex (Braak and
Braak, 1992). Excellent co-registration of individual NFTs
with radiolabelled features was also observed in the high-
power images of case D2 (see supplementary data Figure).
These data indicate that [3H]-PIB can, at a very low
concentration, label pathologic human amyloid deposits











PIB Thioflavin S6E10 CAA-NDB
Fig. 3 Images of adjacent OCL sections from two Category C pathology cases (C1 in A^C; C2 in D^G), showing correspondence of PIB
binding (A and D) with 6E10-immunoreactive Ab deposits (C and F). NDB is demonstrated in sections treated with the non-radioactive
competitive ligand BTA-1 (B and E). Black arrows demonstrate a number of specific corresponding features. Asterisks mark staining
artefacts on 6E10 sections.Note that associated with case C2 (D^F) the majority of the PIB-labelled areas are not completely displaced by
the cold BTA-1 compound and that these additionally coincide with 6E10-labelled foci (black arrows on E and F). Higher power images of
boxed area from case C2 arranged in consecutive cryostat order showing correspondence of PIB binding with 6E10-immunoreactive Ab
deposits, Thioflavin S-stained amyloid deposits and CAA-NDB (G). Blue arrows demonstrate a selection of corresponding amyloidotic
blood vessels. Scale bar 1mm.
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Fig. 4 Representative images of adjacent ECX sections from
Category D pathology cases (D1A-B and D2 C-D) demonstrating
specific binding of [3H]-PIB (A and C). NDB is demonstrated in
sections treated with the non-radioactive competitive ligand
BTA-1 (B and D). Higher power representative images of boxed
area from case D1 arranged in consecutive cryostat order
showing correspondence of PIB binding withThioflavin S and
Gallyas-positive NFT formations (E).White and black arrows
demonstrate a selection of corresponding features. Scale bar1mm.
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Discussion
The data demonstrate for the first time that at tracer
concentrations the neuroimaging agent PIB is not specific
for CPs, one of the defining pathological features of AD,
but that it additionally binds a range of Ab containing
lesions including DPs and CAA. The study also established
that PIB decorates the tau containing amyloid structures
associated with NFTs. However, the contribution of
NFTs to the overall AD-associated PIB retention pattern
is likely to be minor due to the much greater binding
associated with Ab lesions. Taken together these findings
strongly suggest that in vivo [11C]-PIB cortical uptake
primarily reflects Ab-related cerebral amyloidosis (i.e. is a
marker of all fibrillar Ab containing pathology: DPs, CPs
and CAA).
It is worth emphasising that the experimental protocols
used in this study differ significantly from the previous
studies investigating the interaction of PIB with human
brain sections (Klunk et al., 2003; Mathis et al., 2003, 2004;
Bacskai et al., 2007) and that these may explain the novel
findings associated with the current study. First, fresh,
frozen brain sections were utilized in order to maintain the
integrity of both the lesions and the surrounding tissue as
close to in vivo as possible. Secondly, the use of
autoradiography rather than fluorescence techniques per-
mitted the use of concentrations (i.e. low nM range)
relevant to in vivo imaging studies (Mathis et al., 2004;
Rowe et al., 2007), with a detection method insensitive to
potential tissue quenching and auto-fluorescence artefacts.
Thirdly, detailed supporting histological staining was
performed on adjacent sections allowing a direct correlation
with the microscopic lesions.
Relevance of findings to in vivo imaging
studies using PIB
Translation of these findings provides a framework through
which the disparities in PIB cortical uptake and neuro-
pathology patterns can be re-evaluated. Plaque type appears
to have only a minor influence on PIB binding, as both
DPs and CPs are bound with high avidity. PIB uptake in
areas with low CP density (e.g. the striatum) and the lack
of increase in PIB binding associated with clinical disease
progression may both be a consequence of PIB binding to
DPs. Histopathological studies indicate that plaque load,
a measure of both DPs and CPs, may be high in non-
demented individuals (Bouras et al., 1994). While CPs may
increase with further overt disease progression, degradation
and loss of CPs may also occur as late clinical stages are
reached (Brun et al., 1981, 1985; Wegiel et al., 2001).
Cortical uptake of PIB in PET is thus a faithful
representation of the pathological data, i.e. widespread
and dense SP deposition as an early, even preclinical, event
in the pathogenesis of AD.
The presence of the CAA-NDB, in the subgroup of e4
positive cases, highlights the importance of understanding
the interaction of PIB with CAA, due to this fundamental
difference in behaviour compared with SPs. Autopsy
analysis of a ‘PIB-positive’ DLB case indicated that CAA
was the major pathological source of amyloid and suggested
that this lesion type can by itself be a major source of
[11C]-PIB cortical uptake (Bacskai et al., 2007).
Furthermore, our findings are congruent with those from
a study in which the presence of the e4 allele was linked
with a higher cortical uptake of [11C]-PIB, irrespective of
clinical diagnosis (Rowe et al., 2007). CAA is biochemically
different to parenchymal SPs in that it is formed primarily
from Ab 1-40 fibrils, although this varies with neuroana-
tomical location (Attems, 2005). SPs are generally enriched
in Ab 1-42 species and are additionally subjected to a wide
range of post-translational modifications, such as oxidation,
isomerization and N-terminal truncation (Lockhart, 2006).
Although, in vitro data indicates that the interaction of PIB
with fibrils formed from either Ab 1-40 or Ab 1-42 is more
or less identical (Klunk et al., 2005) this does not rule the
possibility that post-translation modifications may selectiv-
ity alter the interaction of PIB with one pool. Additionally,
the observation that the CAA-NDB was not restricted to the
OCL but that it was also observed in the SPL and MFG
regions suggests that it is a generic feature. ApoE-e4 is
linked both with CAA severity (Alonzo et al., 1998;
Chalmers et al., 2003) and conformation changes to
amyloid structure (Sanan et al., 1994), and these factors
combined with biochemical differences in the Ab pools may
account for the occurrence of the CAA-NDB. The data
strongly suggests that all individuals undergoing imaging
scans with all classes of amyloid imaging probes should be
genotyped for ApoE4 and stratified for potential differences
in the patterns or kinetics of ligand retention.
The deposition of Ab lesions is a common neuropatho-
logical finding in a number of conditions other than AD
such as vascular dementia (Alonzo et al., 1998) and DLB
(Tsuboi et al., 2005; Ballard et al., 2006). The current study
clearly supports the continued application of amyloid
imaging as another clinical tool to identify and stratify
dementias based on their cortical Ab load (Rowe et al.,
2007; Rabinovici et al., 2007). Although, the current study
does not directly address the ability of PIB to act as a
pharmacodynamic marker, for drugs targeting Ab metabo-
lism (Pangalos et al., 2005), the data suggests that any
change in the cortical uptake of the ligand cannot be
ascribed to the appearance or disappearance of a particular
Ab lesion type.
It is reasonable to assume that the interaction between
PIB and NFTs is due to the presence of high affinity
binding sites associated with the amyloid fold of the tau,
given that these structures can be labelled by the chemically
related compounds Thioflavin S and T (Dickson, 2005).
The weak labelling of the NFTs, relative to that observed
with the Ab lesions, is consistent with a much lower density
of binding sites associated with this form of amyloid and
that tangles, in contrast to Ab lesions, are therefore unlikely
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to be a significant source of tracer uptake in vivo. This
contention is supported by data from a study using the
PIB-related compound, [3H]-BTA-1, which demonstrated
that the levels of radioligand associated with ECX homo-
genates from an AD case were similar to control case levels
and around 10-fold less than SP-containing frontal cortex
homogenates (Klunk et al., 2003). The higher binding of
[3H]-BTA-1 to the frontal cortex homogenates clearly
mirrors the intense labelling of SPs and CAA relative to the
weakly stained NFTs observed in the current autoradio-
graphy study.
Conclusion
In summary, present data supports the application of
[11C]-PIB as an important tool for determining the
cerebral Ab-related amyloid load associated with AD and
potentially other types of dementia. However, these findings
also provide a molecular explanation for the radiotracer’s
limited (i) diagnostic specificity and (ii) dynamic range for
monitoring disease progression in AD. Alternative amyloid
targeting ligands such as [11C]-SB13 (Verhoeff et al., 2004)
and [18F]-FDDNP (Shoghi-Jadid et al., 2002; Small et al.,
2006) are currently undergoing evaluation studies in
dementia populations; understanding their molecular bind-
ing profile using analogous experimental procedures will be
critical in evaluating their potential as imaging biomarkers.
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Supplementary material is available at Brain online.
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